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Abstract 
Additive manufacturing techniques offer the potential to fabricate organized tissue 
constructs to repair or replace damaged or diseased human tissues and organs. Using these 
techniques, spatial variations of cells along multiple axes with high geometric complexity in 
combination with different biomaterials can be generated. The level of control offered by 
these computer-controlled technologies to design and fabricate tissues will accelerate our 
understanding of the governing factors of tissue formation and function. Moreover, it will 
provide a valuable tool to study the effect of anatomy on graft performance. In this review, 
we discuss the rationale for engineering tissues and organs by combining computer-aided 
design with additive manufacturing technologies that encompass the simultaneous 
deposition of cells and materials. Current strategies are presented, particularly with respect 
to limitations due to the lack of suitable polymers, and requirements to move the current 
concepts to practical application. 
 
Keywords: additive manufacturing; bioprinting; biofabrication; hydrogels; tissue engineering 
 
  
4 of 58 
 
Contents 
1. The rationale 
2. Historical overview 
3. State-of-the-art 
3.1. 2D patterning and direct cell manipulation 
3.2. Additive manufacturing techniques 
3.3. Biomaterials 
 3.3.1 Scaffold materials 
  3.3.2. Hydrogels 
3.3.3. Scaffold-free tissue manufacture approaches 
4. Challenges and current developments 
4.1. Construct design 
4.2. Hardware 
4.3. Biomaterials 
4.3.1. Degradation properties 
4.3.2. Mechanical properties 
4.3.3. Hybrid structures 
4.4. Vascularization 
4.5. Scale-up of the AM process 
4.6. Regulatory and commercial aspects 
5. Future directions 
5.1. Modular tissue assembly 
5.2. Convergence of techniques 
5.3. Automation of pre- and post-manufacturing phases 
5 of 58 
 
5.4. Manufacturing of tissue-like constructs for drug discovery and/or testing 
5.5. In situ additive manufacturing 
6. Conclusion 
References 
 
Nomenclature 
2PP two-photon polymerization 
AM additive manufacturing 
BLP biolaserprinting 
CAD  computer-aided design 
CT computed tomography 
DA diacrylate 
DMD digital mirror device 
ECM extracellular matrix 
FDM fused deposition modeling 
HA hyaluronic acid 
HEMA hydroxyethyl methacrylate 
LCST lower critical solution temperature 
MA methacrylate 
MMP matrix metalloproteinases  
NIPAAm N-isopropylacrylamide  
PEG poly(ethylene glycol) 
PPO poly(propylene oxide) 
RP rapid prototyping 
SFF solid freeform fabrication 
SLA stereolithography (apparatus) 
SLS selective laser sintering 
SPECT single photon emission CT 
STL standard tessellation language 
TEC tissue engineered construct 
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1. The rationale 
The fundamental concept underlying tissue engineering is to combine a scaffold  or matrix, 
with living cells, and/or biologically active molecules to form a tissue engineering construct 
(TEC) to promote the repair and/or regeneration of tissues. The scaffold (a cellular solid 
support structure comprising an interconnected pore network) or matrix (often a hydrogel 
in which cells can be encapsulated) is expected to perform various functions, including the 
support of cell colonization, migration, growth and differentiation. Further, for their design 
physicochemical properties, morphology and degradation kinetics need to be considered. 
External size and shape of the construct are of importance, particularly if it is customized for 
an individual patient [1]. Besides the physical properties of a scaffold or matrix material (e.g. 
stiffness, strength, surface chemistry, degradation kinetics), the micro-architecture of the 
constructs is of great importance for the tissue formation process [2]. In recent years, a 
number of automated fabrication methods have been employed to create scaffolds with 
well-defined architectures [3, 4]. These have been classified as rapid prototyping (RP) 
technologies, solid freeform fabrication (SFF) techniques, or according to the latest ASTM 
standards, additive manufacturing (AM) techniques [5]. With AM techniques, scaffolds with 
precise geometries can be prepared [6], using computer-aided design combined with 
medical imaging techniques to make anatomically shaped implants [7]. Together with the 
development of biomaterials suitable for these techniques, the automated fabrication of 
scaffolds with tunable, reproducible and mathematically predictable physical properties has 
become a fast-developing research area. 
The last few years have seen an upturn in economic activity and successful application of 
newly developed tissue engineering products, which for the largest part has resulted from 
identification of products that are translatable from bench to bedside with available 
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technology and under existing regulatory guidelines [8]. Cell-free scaffolds have shown 
clinical success, e.g. for bone (Fig. 1), osteochondral tissue repair, cartilage and skin [9]. 
Also, strategies to create new vasculature - a critical aspect of tissue engineering - are being 
developed by making use of the body’s self-healing capacity [10]. 
 
Fig. 1. Example of cell-free clinical application of tissue engineering: calvarial 
reconstruction using polycaprolactone-calcium phosphate scaffolds. A. Scaffold designed 
from medical CT imaging data and fabricated by fused deposition modeling B. Calvarial 
defect C. Defect after implantation of scaffold D. CT images showing beginning bony 
consolidation of the defect after 6 months. Reproduced with permission from (2011) 
Georg Thieme Verlag KG [11]. 
 
Nevertheless, cell-based therapeutics have largely failed from both a clinical and financial 
perspective [12, 13]. The developed tissue engineering products were not necessarily 
inferior to previous alternatives, but the efficacy and efficiency were not sufficient to justify 
the associated increases in costs [14,15]. Manual cell seeding and culturing of pre-fabricated 
scaffolds is time-consuming, user-dependent, semi-efficient and, therefore, economically 
and logistically not feasible to achieve clinical application at an economical scale [16, 17]. 
Particular shortcomings of the current tissue engineering paradigm involving cell seeding of 
pre-fabricated scaffolds are the inabilities to: 
 mimic the cellular organization of natural tissues 
 upscale to (economically feasible) clinical application 
 address the issue of vascularization 
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The use of additive tissue manufacturing addresses these points by the incorporation of 
cells into a computer-controlled fabrication process, thus creating living cell/material 
constructs rather than cell-free scaffolds (Fig. 2). The fundamental premise of computer-
controlled tissue fabrication is that tissue formation can be directed by the spatial 
placement of cells themselves (and their extracellular matrix), rather than by the spatial 
architecture of a solid support structure alone. Although still at an early stage of concept 
development and proof-of-principle experiments, it appears that endeavors following this 
approach are the most promising to deliver clinical solutions on the longer term where cell-
free approaches cannot. Automated tissue assembly opens up a route to scalable and 
reproducible mass production of tissue precursors [18]. Furthermore, implementing good 
manufacturing practices (GMP), quality control and legislation are facilitated by the use of 
automated processes.  
 
The aim of this comprehensive review article is to discuss current strategies of AM-related 
tissue engineering applications, particularly with respect to limitations due to the lack of 
suitable polymers and requirements, to move the current concepts to practical application. 
 
Fig. 2. Schematic elucidating the principle of additive tissue manufacturing. A. Imaging of 
an organ to obtain 3D digital blueprint. B. Concurrent additive manufacturing of 
scaffolding structure (biodegradable thermoplastic) and cells suspended in gels: pre-
adipocytes in adipose-mimetic ECM gel and smooth muscle cells in gel mimicking their 
native ECM. C. Manufactured 3D neo-tissue construct. D. Implantation after mastectomy. 
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2. Historical overview 
In the classical picture of manufacturing, objects can be produced either tailor-made on a 
one-by-one basis, or by mass production. Mass-produced goods are much cheaper than 
tailor-made products that usually involve skilled manual labor, yet leave little room for 
customer specifications or requirements. With the advent of AM, this classical picture has 
started to change. AM enables engineers to create objects from personalized specific 
computer-aided designs, while employing automated processes and standardized materials 
as building blocks. Currently, AM technology is still quite expensive for the personal user 
groups, therefore, the fabrication of self-designed objects is mostly outsourced to 
companies, but with fast-developing projects such as Fab@Home [19] it is realistic that in a 
decade from now many households will have their personal AM equipment. As a 3D 
analogue to inkjet and laser printers, this will allow users to fabricate personally designed 
objects in an inexpensive and automated manner. 
 
With respect to medical implants, patients might have individual needs, based on specific 
anatomy or the possibility to include autologous cells to enhance the treatment. The 
combination of automation and flexibility in design is what makes AM very suitable for the 
generation of such personalized implants and devices. The behavior of cells can be directed 
by tailoring their environment. Patterning technologies can control surface chemistry and 
topography at scales smaller than a single cell. They can be designed to mimic the natural 
surroundings and regulatory microenvironments of cells in vivo, or to modify the 
microenvironment to study the cellular response [20-22]. In two dimensions, one has more 
control over the chemical and physical properties on a small scale, and imaging and 
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characterization are simpler. Although a significant body of knowledge on cell behavior has 
been accumulated by using patterned surfaces, two-dimensional (2D) techniques have been 
shown to be insufficient for some new challenges of cell biology and biochemistry, as well as 
in pharmaceutical assays [23]. The importance of a three-dimensional (3D) structure for in 
vitro experiments has been demonstrated by a number of studies [24]. For example, 
hepatocytes retain many of their liver-specific functions for weeks in culture in-between 
two layers of collagen gel, whereas they lose many of these functions within a few days 
when cultured as a monolayer on the same gel [25]. Also, it has been long known that 
chondrocytes retain their phenotype in 3D cultures, whereas they dedifferentiate when 
cultured on flat surfaces [26]. The vascularization of tissue-engineered bone is only possible 
in 3D [27]. The current challenge is to improve 3D tissue manufacture techniques to a higher 
level of control at higher accuracies, aiming to recreate the in vivo niche with automated 
fabrication methods while retaining a clinically relevant production rate. 
A time line starting from the invention of the first printing techniques up to the 
current state-of-the art in AM of TECs is graphically illustrated in Fig. 3 (additional relevant 
breakthroughs in science and technology have also been listed/included). Although 
automated processes dealing with cells, peptides and biomaterials have been around for 
nearly half a century (e.g. the first automated cell sorter was invented already in 1965), the 
first reported attempts to manufacture biological constructs including living cells dates back 
less than a decade. Pioneering work in this kind of printing was done in the Boland 
laboratory, using a simple home-office desktop printer with only minor modifications to 
deposit cells and proteins [28]. Inkjet printing has since then been studied and developed to 
a quite well-understood process capable of patterning viable cells and biomaterials [29]. A 
number of AM techniques have been developed or modified to include cells in the 
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fabrication process, among which biolaserprinting [39, 31] (since 2004), stereolithography 
[32-35] (since 2004) and robotic dispensing [36-44] (which is based on fused deposition 
modeling and also referred to as 3D fiber plotting (3DF) or bioplotting) (since 2005). 
Recently, the very first use of AM directly in vivo was reported (biolaserprinting, 2010) [45]. 
Further, the exponential growth of this new field is illustrated by the establishment of the 
journal Biofabrication in 2009 and the International Society for Biofabrication 
(www.biofabricationsociety.org) in 2010. 
 
Fig. 3. History of additive manufacturing and its application in tissue engineering; the 
introduction of technologies and major scientific findings. 
 
3. State-of-the-art 
It should be understood that, technologically, additive tissue manufacture is still in its 
infancy. Hydrogel structures containing viable cells have been produced, but the designs 
have been simple and isotropic, the dimensions have been limited to a few millimeters and 
the imposed requirement for mechanical properties has been ‘self-supporting’ or 
‘handleable’. Fig. 4 shows the results of some of the most advanced attempts to fabricate 
living constructs of cells and hydrogels with automated processes. These data sets show the 
potential of AM, yet at the same time the limitations and the embryonic stage of its 
development. 
 
Fig. 4. Examples of bioprinted structures. A, B, C: layer-by-layer fabrication of 
gelatin/alginate/fibrinogen containing adipose-derived stem cells (in pink) and 
hepatocytes in gelatin/alginate/chitosan (white). D: fusion of printed cell aggregates for 
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scaffold-free vascular tissue engineering. E: hepatocytes in gelatin/chitosan hydrogel 
structures 1 month post-dispensing. Reproduced with permission from (2009) Elsevier [46] 
and [40, 75] copyright © 2005, 2009. Reprinted by Permission of SAGE. 
 
3.1. 2D patterning and direct cell manipulation 
In vitro 3D models based on engineered human tissues are now emerging as a viable 
alternative to 2D cell culture assays (which often give false predictions due to an 
oversimplified cell environment) and in vivo experiments (which do not necessarily capture 
the important aspects of the human condition, and are limited in the possibility of 
environmental control). Nevertheless, some tissue manufacture techniques such as inkjet 
printing and biolaserprinting have emerged from technologies that initially aimed at the 
manufacturing of 2D systems. Here, we briefly discuss patterning and cell manipulation 
techniques that have been performed in 2D.  
 
Working in 2D has several specific advantages. One has more control over the chemical and 
physical properties on a smaller scale, and characterization (particularly imaging) is easier. 
Using patterning technologies, one can spatially control surface chemistry and topography 
at the micrometer level or even below. Most 2D patterning techniques involve the 
fabrication of a patterned surface by photo-lithography, followed by the selective 
functionalization of the patterned surface with for example cell-adhesive peptides, cell-
repellent polymers or bound signaling molecules. Photolithography provides the unique 
ability to study cell-substrate interactions on single cells in confined areas. A specific 
disadvantage of photolithography is the high cost associated with the equipment and 
cleanroom facilities. Soft lithography uses elastomeric (‘soft’) stamps by casting and curing 
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an elastomer (typically poly(dimethoxy siloxane)) on a silicon master [48]. With these 
stamps patterns of virtually any compound (including proteins) can be transferred onto 
most surfaces, without the use of UV or organic solvents. Using this collection of techniques, 
surfaces have been designed that mimicked the natural surroundings and regulatory micro-
environments of cells in vivo, and micro-environment have been modified to study the 
cellular response [20-22]. Elastomeric stamps have even been employed to directly pattern 
living cells.  
 
Another technique that allows direct manipulation of cells is laser-guided direct writing. 
Individual cells in suspension are guided (based on differences in refractive indices) by 
directed laser-light (‘optical tweezers’) to be deposited onto solid surfaces [49]. The cell-by-
cell deposition theoretically allows the generation of precise patterns of cells, inducing 
specific cell-cell contacts. Furthermore, technologically simpler and less expensive 
alternatives for cleanroom-based photolithography are being developed. These mostly have 
lower accuracies, but still high enough to engineer an environment on the cell-size level. 
Examples are LCD-based projection photolithography [50] and transparency-based 
lithography, where masks are obtained by simply printing patterns onto overhead projector 
sheets with a high-resolution office printer [51]. 
 
Surface patterning and direct cell manipulation techniques have proven to be useful tools to 
study direct cell-material interactions and we conclude that those will remain to be applied 
for this specific purpose. However, the designed micro-environments ultimately need to be 
expanded into the third dimension to be useful for the manufacturing of tissues and organs. 
 
14 of 58 
 
3.2. Additive manufacturing techniques 
With AM techniques, objects from 3D model data sets can be constructed by joining 
material in a layer-by-layer fashion, as opposed to a subtractive manner in which most 
traditional manufacturing methodologies operate. In terms of tissue and organ 
manufacturing, the additive nature ensures minimal waste of scarce and expensive building 
material, namely cells, growth factors and biomaterials. The use of 3D model data enables 
fabrication of customized tissues, which is a conditio sine qua non for patient-specific 
treatment concepts. Further, AM techniques offer a high level of control over the 
architecture of the fabricated constructs, guarantee reproducibility and enable scale-up and 
standardization. The first step to produce a 3D object through AM is the generation of the 
corresponding computer model either by the aid of 3D CAD software or imported from 3D 
scanners [52]; there are a large number of imaging methods for data acquisition of human 
or animal body parts, such as X-ray computed tomography, magnetic resonance imaging, 
ultrasound echoscopy, single-photon gamma rays (SPECT) and bioluminescence imaging [53-
56]. The CAD model is then tessellated as an STL file, which is currently the standard file for 
facetted models. Before manufacturing, the STL model is mathematically sliced into thin 
layers (sliced model), which are reproduced into a physical 3D object by the AM device. 
Several well-developed and commercially available AM techniques have been employed to 
design and fabricate scaffolds for tissue engineering applications (Table 1). 
 
Table 1: Description of four common, commercially available AM techniques that are often 
employed in the preparation of scaffolds. 
((insert FDM.TIF here)) Melt extrusion/fused deposition modeling 
(FDM): By this process, thin thermoplastic 
filaments or granules are melted by heating 
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and guided by a robotic device controlled by a 
computer, to form the 3D object. The material 
leaves the extruder in a liquid form and 
hardens immediately. The previously formed 
layer, which is the substrate for the next layer, 
must be maintained at a temperature just 
below the solidification point of the 
thermoplastic material to assure good 
interlayer adhesion. 
((insert SLA.TIF here)) Stereolithography (SLA): With this process 3D 
solid objects are produced in a multi-layer 
procedure through the selective photo-
initiated cure reaction of a polymer. These 
processes usually employ two distinct 
methods of irradiation. The 1st method is a 
mask-based method in which an image is 
transferred to a liquid polymer by irradiating 
through a patterned mask. The 2nd method is a 
direct writing process using a focused UV 
beam produces polymer structures. 
((insert 3DP.TIF here)) 3-Dimensional printing (3DP): The process 
deposits a stream of microdroplets of a binder 
material over the surface of a powder bed, 
joining particles together where the object is 
to be formed. A piston lowers the powder bed 
so that a new layer of powder can be spread 
over the surface of the previous layer and then 
selectively joined to it. The process is repeated 
until the 3D object is completely formed. 
((insert SLS.TIF here)) Selective laser sintering (SLS): This technique 
uses a laser emitting infrared radiation, to 
selectively heat powder material just beyond 
its melting point. The laser traces the shape of 
each cross-section of the model to be built, 
sintering powder in a thin layer. After each 
layer is solidified, the piston over the model 
retracts to a new position and a new layer of 
powder is supplied using a mechanical roller. 
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AM technologies produce 3D parts by spatially directed manipulation of materials in several 
possible ways: thermal, chemical, mechanical and/or optical. In thermal processes, the 
material is formed into an object after which it undergoes a thermal transition to fix the 
shape. In chemical-based processes, the manufactured shape is fixed by a chemical reaction 
(often polymerization). Mechanical processes rely on the physical deposition of cells or 
materials, and in optical processes cells or polymers are manipulated using light. Often 
several processing modes are combined in an AM technique (Table 2). 
 
Table 2: Characteristics of AM techniques that are used for the preparation of cell-laden 
constructs and cell-free scaffolds for tissue engineering. Processing modes are indicated by 
‘t’ for thermal processing, ‘c’ for chemical, ‘m’ for mechanical and ‘o’ for optical, where 
modes in brackets are optional. 
technique processing 
modes 
accuracy 
(m) 
materials cells advantages disadvantages Refs 
inkjet printing 
(thermal or 
piezo-electric) 
t/m, (c) 20-100 liquids 
hydrogels 
yes use of existing 
cheap 
technology, 
multiple 
compositions 
low viscosity 
prevents 
build-up in  
3D, low 
strength 
[28, 
57-64] 
3D printing m, (c) 50 polymers, 
ceramics 
no multiple 
compositions 
requires 
powder, 
cell-unfriendly 
environment 
[65-67] 
stereolithography 
(incl. two-photon 
polymerization) 
o, c 0.5-50 hydrogels 
polymers 
ceramic-
composites 
yes high accuracy single 
composition, 
requires 
photo-curable 
material 
[32-35, 
68-70] 
laser direct 
writing 
o 20 cells in media yes single cell 
manipulation 
no structural 
support, 
scalability 
[49] 
direct writing m, c 1 polyelectro-
lytes 
not 
yet 
high accuracy requires 
solvents, cell-
unfriendly 
[71, 
72] 
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environment, 
scalability 
melt extrusion 
(including FDM) 
t, m 100 thermoplastics 
composites 
no technologically 
simple 
requires 
strong 
filament and 
high temp. 
[73, 
74] 
robotic 
dispensing 
 
m, (t), (c) 100 hydrogels 
polymers 
ceramic-
composites 
yes multiple 
compositions 
relatively low 
accuracy 
[36-44] 
selective laser 
sintering 
o, t 50 polymers, 
ceramics 
no  requires 
powder, 
cell-unfriendly 
environment 
[75, 
76] 
biolaserprinting o, t 10 liquids yes high accuracy 
at high speed 
low viscosity 
prevents 
build-up in  
3D 
[30, 
31] 
robotic assembly m 5 rigid solids not 
yet 
no heat, light 
or reaction 
required 
expensive 
machinery 
[77] 
 
In general, techniques that use optics can achieve the highest resolutions. Examples of 
accurate optical fabrication methods are stereolithography, laser direct writing and 
biolaserprinting. Additionally, photo-initiated polymerization can be used for safe 
encapsulation of cells and exogenous growth factors into hydrogels. Thermal techniques 
such as selective laser sintering or fused deposition modeling are not compatible with cells if 
requiring supra-physiological temperatures, but they can be adapted for processing 
thermosensitive hydrogels. Mechanical processes often allow for including cells in the 
fabrication process, as long as shear stresses induced on cells such as by deposition through 
a needle or inkjet cartridge orifice are sufficiently low. 
 
Stereolithography is the oldest, most developed and most accurate of all AM technologies, 
and it has been applied for several biomedical applications including the fabrication of TECs 
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with encapsulated living cells [68]. Although it is one of the few techniques with accuracies 
comparable to the size of a cell, its use has not been favored because to date, a system has 
not yet been developed that enables handling of different compositions of materials and/or 
cells. Pioneering work on tissue manufacture has been done using inkjet and laser printing. 
However, over the last few years the focus has been mostly on the robotic dispensing of 
hydrogels with encapsulated cells. With this class of techniques, highly viscous cell 
suspensions or liquid gel precursors are dispensed from cartridges or syringes through a 
nozzle and deposited as strands (Fig. 2). The method is versatile in terms of materials that 
can be used, in controlling the environmental conditions and in varieties of dispensing 
mechanisms (pneumatic, syringe pumps, extruder screws). The versatility and limited 
technological complexity are perhaps the main reasons for the relatively wide commercial 
availability of dispensing ‘bioprinters’. A less-developed method that technologically could 
be applied to make living constructs in an automated manner is robotic assembly. High-
precision robotic grippers can assemble pre-fabricated microscale building blocks into larger 
structures [78], and these building blocks could potentially be pre-seeded with different cell 
types. (a video of robotic assembly is available online as Supplementary Information). 
 
3.3. Biomaterials 
Over the last two decades, several biodegradable materials have been used and developed 
for the design and fabrication of scaffolds and matrices, including polymers (natural and 
synthetic) [79, 80], ceramics [81] and composites [82]. The polymeric and ceramic materials 
that have been processed by AM to prepare scaffolds have all, with a few exceptions, been 
modified or synthesized specifically for use with a single AM technique, enabling accurate 
and reproducible fabrication of well-defined architectures with the anticipated  
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physicochemical properties. However, these materials typically require process parameters 
(e.g., high temperature, solvents, lack of water) that are not conducive to direct inclusion of 
cells. Hydrogels are thus gaining increasing interest for the manufacturing of tissues [83].  
 
3.3.1. Scaffold materials 
Scaffolds for tissue engineering are mostly prepared from polymers, ceramics, or their 
combination (composites). To obtain an interconnected pore network many techniques 
have been employed including porogen leaching, gas foaming and phase-separation/freeze-
drying. AM techniques however offer a higher degree of control over scaffold architecture 
[3], and a range of materials can be processed by AM techniques (Table 2). 
Stereolithography, the oldest and most developed of AM techniques, requires a photo-
curable material. It has been employed to prepare scaffolds from poly(propylene fumarate) 
[84] and from (meth)acrylated poly(trimethylene carbonate co caprolactone) [85], 
poly(lactide) [86], polycaprolactone [87] and poly(ethylene glycol) [32-35], mostly in the 
presence of a diluent that can be either reactive or unreactive. Composites have been 
prepared by mixing in small ceramic particles in the stereolithography resin [88], and pure 
ceramic structures were realized by preparing composite structures with high ceramic 
loading, followed by burning out of the polymer while simultaneously sintering the ceramic 
[89]. 
Selective laser sintering has been used to prepare porous polycaprolactone (PCL) scaffolds, 
with or without additional calcium phosphate particles [76]. FDM-based tissue engineering 
research has revolved around this polymer as well, leading to clinical application in the 
maxillofacial arena [11] and the establishment of bone tissue engineering concept based on 
a large long bone defect model in sheep [27]. 3DP has been applied to both synthetic and 
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biopolymers (polylactide [65] and starch [66], respectively), as well as ceramics 
(hydroxyapatite [67]). Direct writing, a process similar to robotic deposition but at much 
higher resolutions achievable through to electrostatic interactions and coagulation, has 
been employed to fabricate well-defined silk fibroin scaffolds [72]. Although all mentioned 
materials are suitable for fabrication of scaffolds, the toxicity of their precursors or 
processing conditions often still does not allow the co-deposition of cells or cell-laden 
hydrogels in the manufacturing process. However, recent developments have shown a 
convergence of scaffold fabrication and cell deposition, combining the mechanical support 
of a scaffold structure with the automated and controlled placement of cells. These hybrid 
structures are discussed in detail in section 4.3.3. AM has proven its value for the 
preparation of scaffolds, and it is expected that current materials and processes will be 
adapted, and new ones will be put into place to allow the inclusion of cell-laden hydrogels in 
the fabrication process. 
 
3.3.2 Hydrogels 
Hydrogels are polymeric networks that absorb water while remaining insoluble and 
preserving their characteristic three-dimensional structure. This is because of the large 
number of physical or chemical links between the polymer chains. Hydrophilicity is one of 
the main factors that determine the biocompatibility of hydrogels, thus making them 
attractive for application in medicine and pharmacy as drug and cell carriers, and specifically 
for the design and fabrication of TECs [90].  
As a result, they can provide embedded cells with a 3D environment similar to that in many 
natural tissues. Hydrogels are usually classified as either naturally-derived or synthetic. 
Naturally-derived gels (often derived from ECM itself) are generally good cell support 
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materials, but have intrinsic problems, such as batch-to-batch variation, limited tunability 
and possibility of disease transfer. Synthetic hydrogels bear none of these disadvantages, 
but often lack biofunctionality. Besides these two classes of hydrogels, hybrid gels having 
both natural and synthetic components are gaining increased interest in tissue engineering, 
and more recently, in additive tissue manufacture. For example, naturally-derived hydrogels 
such as gelatin, hyaluronic acid and dextran have been functionalized with methacrylate or 
methacrylamide groups to enable (photo-initiated) cross-linking in combination with robotic 
dispensing [44, 91]. The methacrylate chemistry that was used here and before also for 
synthetic polymers, is versatile and can be applied to more naturally-derived hydrogels, 
including alginate [92]. The introduction of chemical cross-links at controlled densities not 
only enables fixation of printed shapes, but also allows tailoring of mechanical properties, 
swelling behavior, degradation kinetics and so forth. The chemical modification of naturally-
derived hydrogels allows for combination of their intrinsic biofunctionality with the 
tunability of many properties through these synthetic components. On the other hand, 
synthetic gels are increasingly being functionalized with biologically active components such 
as cell-adhesive peptides, covalently bound growth factors, heparan sulphate, and protease-
cleavable cross-links [93]. 
 
In additive tissue manufacturing, hydrogels are used both as a building material and as a cell 
delivery vehicle. Cells that have been viably encapsulated within hydrogels include 
fibroblasts, chondrocytes, hepatocytes, smooth muscle cells, adipocytes, neuronal cells and 
stem cells [94]. During the AM of 3D tissue constructs, a hydrogel precursor solution with 
suspended cells needs to be processed into a defined, designed shape that is subsequently 
fixed by gelation. Therefore, the viscosity of the suspension needs to be sufficiently high to 
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overcome surface tension-driven droplet formation, to enable drawing of thin strands of 
material, i.e. create well-defined shapes, and to prevent cells from settling during the 
fabrication process. A relatively quick gelation is subsequently required to retain the shape 
of the fabricated structure. This gelation is usually a cross-linking reaction initiated either by 
light, by a chemical, by hydrophobic or complexation interactions, or by a thermal 
transition. Both the shaping of the construct and this cross-linking reaction obviously should 
not compromise cell viability. Another requirement is adequate mechanical properties to 
retain the designed and fabricated shape. Most manufacturing processes impose stricter 
requirements on the mechanical properties of the gels than when casting and molding. 
Large structures with included porosity can only be accurately and reproducibly prepared 
when the elastic modulus and gel strength are sufficiently high. 
 
Besides these constraints related to manufacturing, the hydrogel has to meet the demands 
for cell encapsulation and tissue development. Most hydrogels used in tissue engineering 
are chemically cross-linked, which means they are 3D networks of polymer chains with 
meshes that are orders of magnitude smaller than cells. This has a large restricting effect on 
the mobility of encapsulated cells; predominantly cell migration, as well as proliferation is 
completely arrested until degradation of the gel takes place [93]. However, degradation 
sites can be incorporated into hydrogels, allowing for cell-mediated matrix degradation 
permitting migration and proliferation [95-97]. Degradation of the matrix can also be 
hydrolytically driven [98], or even light-driven through incorporated photo-degradable 
linkers [99]. Cell proliferation and migration are not always essential in the initial stage after 
encapsulation; in cartilage tissue engineering, for example, cells are often encapsulated at 
high densities with the aim of achieving high matrix production. Here, still the mesh size is 
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important as it influences the diffusion of secreted proteins and glycosaminoglycans 
throughout the gel [100]. For the engineering of tissues where proliferation, remodeling and 
vascularization are required (Fig. 2), the hydrogel should allow space for these processes to 
occur. Designed macroporosity in the construct can aid in vascularization, as demonstrated 
by branched vascular networks becoming an integral part of a manufactured tissue [46]. 
 
A particular challenge in additive tissue manufacturing using cell-laden hydrogels is to 
develop a polymer along with processing conditions that are appropriate for both accurate 
printing and cell culture. Often, these criteria impose opposing requirements. For accurate 
printing of form-stable structures, high polymer concentrations and cross-link densities are 
desired, whereas for cell migration and proliferation and subsequent ECM formation both 
need to be low. For example, a currently used naturally-derived printable biopolymer, 
namely calcium-cross-linked alginate, has only a small processing window of in which both 
printing and cell culture are possible: the bioprinting window (Fig. 5A). This bioprinting 
window can be defined for other hydrogel systems by varying the polymer concentration 
and cross-link density and assessing the influence on printability and support for cell culture. 
Often the bioprinting window will be small, if at all present. The example in Fig. 5B shows a 
semi-quantitative assessment of the printability of alginate gels with a pressure-assisted 
microsyringe, in the form of a fidelity phase diagram. Two processing parameters are varied, 
the velocity of the micropositioners and the extrusion pressure, at two distinct hydrogel 
precursor viscosities (or concentrations), and the fidelity of the resulting structure is 
assessed on a semi-quantitative scale ranging from a 'blob' structure to a high fidelity 
structure. The same group has also systematically investigated the effect of shear stress 
endured during the deposition on cell viability and function [101]. After several years of 
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predominantly proof-of-principle studies demonstrating the (bio)printability of a gel with a 
particular AM system, researchers are increasingly optimizing gel parameters and 
processing conditions in systematic and quantitative ways. 
  
Fig. 5.  A. Processing window for bioprinting of alginate hydrogels cross-linked by divalent 
calcium ions. Printing imposes minimum values for alginate and calcium concentrations. 
Cell culture imposes maximum values, leaving a small window for bioprinting. B. 3D phase 
diagram of microfabrication of sodium alginate/calcium at two distinct alginate 
concentrations, showing the influence of velocity of the micropositioners and extrusion 
pressure on the fidelity of the final shape. Reproduced with permission from (2009) ASME 
[102] and (2009) IOP [103](doi:10.1088/1758-5082/1/4/045002). 
 
Most attempts of additive tissue manufacturing so far have utilized hydrogels designed for 
purposes other than AM (Table 3). However, the development of polymers specifically for 
AM of cell-laden constructs has been explored to a limited extent, and may help overcome 
the limitations of current gels and expand the bioprinting window. One of the few examples 
of a hybrid gel tailor-made for AM is based on a PEG-PPO-PEG block copolymer. The 
thermosensitive block copolymer conveniently allows for dispensing a cell suspension at 
ambient temperature, which solidifies upon collecting at 37 °C. However, although most 
cells remain viable during the plotting process, the gel does not support cell viability in 
culture; all cells die within a few days, while the thermogel slowly dissolves into the culture 
media [42]. By functionalizing the terminal hydroxyl units of PEG-PPO-PEG with a peptide 
linker followed by a methacrylate group, a mechanism for covalent cross-linking, as well as 
biodegradability have been introduced, resulting in increased viability over 3 weeks of 
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culture  [104]. A similar approach of a synthetic gel that allows for both thermal gelation as 
well as UV-initiated chemical cross-linking was recently demonstrated by the same group 
[36]. The polymer is an ABA block copolymer composed of poly(N-(2-
hydroxypropyl)methacrylamide lactate) A-blocks and hydrophilic poly(ethylene glycol) B-
blocks of a molecular weight of 10 kDa. The hydrophobic A-blocks not only induce lower 
critical solution temperature (LCST)-behavior employed for printing, but are also partly 
derivatized with methacrylate groups that allows for photo-polymerization for increased 
strength and shape stability.  
 
Photo-cross-linkable gels that do not exhibit thermal gelation have also been printed. In one 
example, methacrylated dextran was mixed with high-molecular weight hyaluronic acid to 
obtain high viscosity for geometrical stability during printing [44]. Although the high 
viscosity enables printing of a porous structure that can be fixed subsequently by photo-
cross-linking, the diameter and spacing of printed strands are considerably larger than for 
LCST-gels. It is expected that development of more hydrogels tailored for specific AM 
techniques will greatly increase the potential of AM. 
 
Table 3: Hydrogels used for additive manufacturing of cell-laden tissue engineering 
constructs. 
Hydrogel Technique Viability Proliferation Refs 
 
Natural 
    
Collagen dispensing 86% 30 % in 24 h [38] 
Gelatin disp. + aldehyde  X-linking 98% none (3 months) [41] 
Matrigel dispensing 99% none (2 weeks) [42] 
Agarose dispensing 93% none (2 weeks) [42] 
Alginate dispensing 94% N/A [37] 
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 dispensing 91% none (2 weeks) [42] 
 
Synthetic 
    
PEG-DA stereolithography 65% N/A [34] 
PEG-PPO-PEG dispensing 84% > 95 % cell death in 3 days [42] 
PPO-PEG-Ala-
MAm1 
disp. + UV X-linking 75%  none; after 3 days 60 % 
viable, up to 3 wks 
[10
4] 
PEG-
HPMALA2 
disp. + UV X-linking 94% 
(1d) 
N/A [36] 
  85% 
(3d) 
  
Hybrid     
HA-SH + 
PEG-4A 
gel rod deposition 100% 10-50 % in 4 days [10
5] 
Gelatin-MA + 
HA-MA 
disp. + UV X-linking 100% doubling in 7 days [91] 
Hyaluronan + 
dextran-
HEMA 
dispensing + UV X-linking 94% 
(1d) 
75% 
(3d) 
N/A [44] 
 
3.3.3. Scaffold-free tissue manufacture approaches 
A relatively new trend in tissue manufacturing is the endeavor to use cells or aggregates of 
cells as building blocks to manufacture tissue engineering constructs without additional 
biomaterials. The rationale is that aggregates of cells can fuse through cell-cell and cell-ECM 
interactions to form larger structures, similar to embryonic development [106]. As cell-cell 
contact can be advantageous to direct tissue formation, it is believed that instead of 
suspended single cells, aggregates of thousands of cells (also referred to as tissue spheroids 
or embroid bodies) should be used for tissue manufacture. An elegant example of this 
approach (although still using agarose rods as a molding template) is the preparation of 
vascular grafts from cell aggregates (Fig. 4D [46]). The beneficial effect of using high 
                                                        
1 PEG-(PPO)2 blockcopolymer functionalised with alanine-methacrylamide end-groups 
2 PEG-(N-(2-hydroxypropyl)methacrylamide lactate)2 blockcopolymer 
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densities of cells and their associated ECM has also been demonstrated for cartilage repair 
[107]. Superficial and middle zone chondrocytes recovered after alginate culture were 
layered without additional biomaterials, resulting in continuous cell-derived tissues with 
different properties in each layer. 
 
Another strategy that aims to engineer material-free implantable tissue is the so called “cell-
sheet technology”. Cells are cultured on a thermo-responsive polymer-coated dish to form a 
self-supporting sheet of cells embedded in their self-produced ECM, which can be harvested 
by a reduction in temperature that renders the surface hydrophilic and hence cell-repellent 
[108]. In this way, cells can be harvested without destroying cell-cell contacts by trypsin. 
Over the last decade, cell-sheet technology has evolved to engineer several tissues with one 
or more cell types, and it has recently seen clinical applications [109]. So far, cell sheet 
technology has only been applied successfully for the regeneration of sheet-like tissues, 
such as the cornea, and as cardiomyocyte patches to repair partial heart infarcts. A next 
step in technological development is needed to create thick 3D tissue structures. 
Potentially, robotics could be employed to automate the cell sheet production process and 
to assemble 3D structures by stacking cell sheets, as the handling steps for cell sheet 
harvesting and stacking are fairly simple with high level of standardization. Obviously, many 
sheets are needed to build a substantial 3D tissue volume and the resulting high cell 
densities will require sufficient vascularization to sustain cell viability.  
 
Recent technological development includes micro-patterned co-culture of fibroblasts and 
endothelial cells as a strategy to generate pre-vascularized tissue from stacks of cell sheets 
[110]. Other potential approaches include the combination of cell sheets with dispensing 
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techniques, to achieve a third dimension by deposition of structured hydrogels onto and in-
between cell sheets. Either way, the current literature predicts that the cell sheet 
technology will play an increasingly important role in the additive tissue manufacture in the 
future. 
 
4. Challenges and current developments 
4.1. Construct design 
A digital blueprint of an organ or tissue is a first requirement to produce an anatomically 
accurate TEC. Medical imaging techniques such as computed tomography and magnetic 
resonance imaging have been used to make anatomically shaped implants using 
intermediate moulds [111, 112] or by direct manufacturing [113]. More recently, 3D laser 
scanning was introduced to obtain digital 3D images of body contours, for example for the 
preparation of tailored breast prostheses implanted after mastectomy in breast cancer 
patients [114]. The obtained digital geometrical blueprint needs to be converted to a 
buildable, heterogeneous model representation describing material composition, 
distribution and geometrical information. Most AM techniques use only one material for 
building a construct, and only geometrical information is needed. Tissues however are 
heterogeneous, comprising of different ECM components, cell types and cell densities, such 
as the osteochondral tissue (Fig. 6). Methods have been developed to model and design 
functionally graded architectures with multiple biomaterials for AM [115-117]. These 
methods will need to be applied to approximate the complex nature of native 
heterogeneous tissues in manufactured cell-material constructs. Only in this way can one of 
the major advantages of including cells in the fabrication process really be exploited, by 
deposition of different cell types according to the tissue blueprint. 
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 Fig. 6. Example of functional graded construct design for osteochondral tissue. The 
differences in tissue composition, mechanical properties and cell type in the native tissue 
are reflected in the design for the manufacturing process by material/hydrogel 
composition, construct architecture and encapsulated cell type. Reproduced with 
permission from (2009) Future Medicine [118] (2009) Mary Ann Liebert [119] and (2009) 
Wiley [121]. 
 
The standard file format to feed geometrical information to AM control softwares is the STL 
format (Standard Tessellation Language). The format makes use of meshes of triangles that 
create watertight outer surfaces of objects. This works well for solid objects with limited 
complexity (which is usually the case for rapid prototyping of solid parts) that are to be built 
from a single material. Some AM control softwares give the user a degree of control over 
porosity, for example by controlling the filament distance that is used to create the tool 
path for deposition-based techniques. A novel modeling approach was recently introduced 
that automatically creates a tool path that fills set regions of a solid STL model, enabling to 
create distinct regions with variable porosity [121]. 
 
However, if the internal pore architecture is to be an integral part of the computer-aided 
design, the STL format an impractical one. An STL mesh of a few mm-sized scaffold with 
well-defined porosity easily exceeds one million triangles, taking up hundreds of megabytes 
of disk space and requiring heavy computation power to design and manipulate. However, 
the pore architecture of constructs with infinite volumes can be described using a single line 
of mathematical equation, with freedom to design different pore shapes, pore sizes and 
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porosity, and allowing to include features such as porosity and pore size gradients [69]. A 
more versatile file format that would allow combining such a porosity function with a mesh 
that describes the macroscopic shape of an organ would make designing and manufacturing 
tissue and organ constructs much more achievable. Until then, computer designs of porous 
structures will be restricted to either a coarse porosity for large models, or small structures 
in the case of finer, well-defined porosity. 
 
A new route to create porous models from medical imaging-derived data was recently 
developed [122]. Existing methods were adapted that convert CT-derived anatomical data 
into a volumetric mesh that can be used e.g. for studying biomechanics using finite element 
modeling [123]. In this case, the mesh is used to create a completely interconnected strut-
based porous model. In practice, the solid model obtained by imaging is seeded with points 
at a given distance (seeding distance SD), which are connected by the finite element 
software to result in a 3D mesh of tetrahedrons. Subsequently, struts of a given thickness 
(ST) are designed around each edge of all tetrahedrons, and these struts are joined at their 
intersections to create a watertight model. Using this method, one can generate porous 
models that have the overall shape of the scanned tissue and/or organ, built up from fully 
connected straight struts to ensure manufacturability and optimal mechanical stability. The 
pore size and porosity can be tailored by controlling the density of seeding points in the 
creation of the tetrahedron mesh, as well as by choosing an appropriate strut thickness (Fig. 
7). The example given in this review demonstrates how from a solid breast model obtained 
by 3D scanning, a range of scaffold morphologies and porosities can be designed and 
fabricated to the requirements of the project objectives and aims. 
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Fig. 7. Generating personalized scaffolds for breast reconstruction. Top-row: CAD-data of 
solid model and porous ‘skeleton-mesh’. Middle row: CAD models with varying pore size 
and porosity as a result of different seeding distances (SD) and strut thicknesses (ST). 
Bottom row: physical prototype models manufactured by fused deposition modeling. 
Reproduced with permission from (2011) IOP [103]( doi:10.1088/1758-5082/3/3/034114). 
 
4.2. Hardware 
Initially, tissue manufacture has focused on the use of inkjet and laser printers. However, 
printing is inherently a 2D process. Inkjet printers are not designed to fabricate 3D 
structures. The upper threshold for viscosity of the ink (30 mPa .s) excludes the use of many 
hydrogels and impedes the build-up of large 3D structures. This limitation also applies to 
biolaserprinting in its current form, and to laser direct writing. To construct functional 
tissues and (ultimately) organs, techniques are required that are capable of building 
structures at relevant scales and accuracies. We conclude that AM techniques possess this 
capability.  
Existing AM devices are currently being modified to facilitate tissue manufacturing. This 
often entails control of the environmental properties (temperature, humidity, and sterility) 
and downscaling of containers, feeders, etc., to reduce loss of costly biomaterials and cells. 
Over the last few years, AM devices designed particularly for tissue manufacture have 
become commercially available, with an emphasis on robotic dispensing techniques [124]. 
Dispensing is a technologically straightforward method to create designed structures at 
relatively high speeds. The largest challenge for the dispensing technology component is to 
build tissues with high accuracy. Liquid precursors need to be dispensed in thin strands from 
small-diameter tips and solidify quickly before spreading out initially on the platform and 
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later on the subsequent layer (a video of dispensing hydrogels is available online as 
Supplementary Information). When only materials are dispensed, this can be achieved by 
employing high polymer concentrations and a non-solvent for quick coagulation. In this way, 
well-defined structures have been prepared from filaments of only 1 m diameter [71]. 
However, for encapsulating cells non-solvents cannot be used and polymer concentrations 
must be lower, so cell-laden hydrogel structures typically have strands with diameters of 
100 m or larger. 
 
Light-based curing techniques are generally more accurate than dispensing techniques. With 
photo-lithography and micromolding, cell-laden microgels with well-defined geometry of up 
to several hundreds of m have been prepared [125, 126]. Two-photon polymerization 
(2PP) has been employed to locally functionalize hydrogels with RGD-peptide sequences, 
leading to directed cell migration with accuracy below 100 m. As a light-directed AM 
technique, stereolithography can be performed at a large scale-range; from decimeter-sized 
objects down to sub-micron features can be built. Such high accuracy, combined with high 
versatility and freedom of design (particularly compared to dispensing techniques) results in 
the ability to create highly detailed organic shapes, such as the alveoli (Fig. 8.), fabricated  by 
2PP-based microstereolithography [127]. The woodpile structure in the bottom row of Fig. 8 
would not be functional as a scaffold for the pores are too small to facilitate cell ingrowth, 
but does illustrate the high level of geometric control that can be achieved with optical 
techniques.  Well-defined structures have been prepared at a resolution of several tens of 
m from hydrogels that were also used for cell encapsulation using the same 
stereolithography setup, although complex and clinically relevant sized hydrogel structures 
with encapsulated cells at such resolutions still await to be reported. 
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 Fig. 8. Two examples of structures prepared by two-photon polymerization (2PP) 
techniques. A. CAD image of a pulmonary alveolar fragment. B.  SEM image of a fabricated 
alveolus. C, D. Woodpile structure resembling an FDM-fabricated scaffold, albeit at about 
100x smaller scale. Reproduced with permission from (2011) Springer. 
 
In the authors’ opinion, the largest challenges to overcome for light-based techniques are 
long fabrication times, and gravitational settling of cells in the precursor solution. One of the 
first reports on stereolithographic fabrication of hydrogel structures in 2005 argued that the 
stereolithography fabrication process was too slow for cell encapsulation; however, 
controlled spatial distribution of cell-adhesive peptides could lead to controlled cell seeding 
and diffusivity throughout the scaffold, which in addition to the presence of channels would 
be superior to traditional seeding and culturing cells on scaffolds [128]. More recently, a 
modification of a stereolithography apparatus for the fabrication of PEG-diacrylate-based 
hydrogel structures with encapsulated cells was reported (Fig. 9) [70]. To prevent cells 
settling to the bottom of the tank due to gravity, each layer of cell-containing prepolymer 
solution was manually added prior to curing of that layer. Besides achieving a homogeneous 
cell distribution, this also allows to use multiple gel compositions and cell types, which is not 
generally possible using the stereolithography technique [68]. In this case the cell 
suspension is still dispensed manually, but one can easily envision automation of this step. 
 
Fig. 9. A schematic representation of the ‘bottom-up’ SLA modification, in which the 
prepolymer solution is pipetted into the container one layer at a time from the bottom to 
the top. [70] - Reproduced by permission of The Royal Society of Chemistry. 
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Another approach for partially automated layered photo-patterning of cell-laden hydrogels 
uses masks printed on a commercial high-resolution printer [129]. A UV curing unit was 
employed with the masks to cure a PEG-DA cell suspension in a chamber that was replaced 
for each subsequent layer, with washes and refilling in-between. The researchers performed 
an extensive biological characterization including optimization of the gel system (among 
which type and concentration of adhesive peptides) and demonstration of the increased 
metabolic activity of hepatocytes encapsulated in perfused patterned hydrogels as 
compared to bulk hydrogels. 
 
Besides layer-by-layer deposition just prior to photo-cross-linking, other solution paths to 
cell settling are possible. For example, by continuous tumbling of the setup, gravity can be 
counteracted by centrifugational forces, creating a micro-gravity environment in which cells 
do not settle. Otherwise, a physical gel could be employed as the (chemical) hydrogel 
precursor in which cells do not settle, rather than using a liquid solution. In this case, a 3D 
pattern could be cross-linked by moving the focal volume of one laser, several lasers 
creating an interference pattern, or by 2PP. After cross-linking of the 3D structure, the non-
cross-linked volume including cells could be removed by reversing the physical gelation (for 
example, warming up of gelatin-methacrylate or ion exchange for an alginate-based gel) and 
recovered for later use, leaving a porous and structured hydrogel with encapsulated cells. 
Even if settling of cells is prevented, speed still is an important processing parameter. When 
working at higher resolution it generally takes longer to build up a specific volume, and this 
is also the case for stereolithography. However, new technologies are being developed to 
increase production speed. For example, as opposed to illumination by a computer-
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controlled laser tip drawing over the surface in most conventional SLAs, some new 
apparatus are equipped with a digital mirror device that enables projection of a whole layer 
at once, thereby significantly increasing fabrication speed [35, 68]. 
 
A current development in stereolithographic AM that aims at high-throughput 
manufacturing of accurate multi-material parts by a new process named stereo-thermal-
lithography [130]. It employs UV radiation and thermal energy (produced by IR radiation) 
simultaneously to initiate the cross-linking polymerization reaction in a medium containing 
both photo- and thermal initiators. The amount of each initiator is low enough not to start 
polymerization by only one of these two effects. However, at a point where the two effects 
coincide, the amount of radicals generated is sufficiently high to initiate the polymerization 
process. Temperature is used to both produce radicals through the fragmentation of 
thermal initiators and simultaneously to increase the initiation and reaction rate of the 
photo-initiated curing reaction. Added to this system is a rotating multi-vat that enables the 
fabrication of multi-material structures (Fig. 10). 
 
Fig. 10. The stereo-thermal-lithographic process with multi-vat system. Liquid resins are 
solidified locally by co-illumination from a UV (light) and an IR (heat radiation) source, 
both patterned using computer-controlled digital mirror devices. The rotating multi-vat 
system enables the construction of multi-material constructs Reproduced with permission 
from (2011) Springer [130]. 
 
4.3. Biomaterials 
36 of 58 
 
For application in additive tissue manufacture, biomaterials must meet more stringent 
requirements than for most other applications such as in food, pharmaceutics or sensors. 
Nevertheless, some innovations from other fields might possibly be translated to AM 
techniques and cell encapsulation, using alternative components and processing conditions. 
This section gives an overview of such developments. 
 
4.3.1. Degradation properties 
Polymer network chains give hydrogels their mechanical stability, but at the same time 
restrict the mobility for cells to migrate and proliferate. Therefore, it is important to match 
the kinetics of degradation with firstly the cell migration and proliferation and subsequently 
tissue formation, such that the newly deposited ECM can take over the load to a certain 
extent from the partially degraded polymer network. Moreover, the rate of tissue formation 
and remodeling depends on many factors and is different for various tissues. Hence, it is of 
utmost importance to study those in vitro and/or in vivo mimetics in great detail [4].  
 
By far most developments on degradable hydrogels for cell encapsulation have been based 
on the water-soluble, bioinert polymer poly(ethylene glycol) (PEG) [93]. In itself it is a non-
degradable polymer, but PEG oligomers that are low enough in molecular weight to be 
secreted by the kidneys are often the basis for the synthesis of degradable macromers 
[131]. These can be (photo)polymerized from aqueous solutions with suspended cells, to 
form cell-laden hydrogels [132]. The degradation kinetics of these gels can be tuned by 
variation of the polymer concentration and molecular weight, the choice of degradable co-
monomer and the ratio of PEG to the degradable component. Furthermore, different cross-
linking mechanisms lead to different network structures with varying degradation profiles 
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(Fig. 11). Addition type chain-cross-linking, step-growth end-linking and mixed-mode 
mechanisms all allow cell encapsulation and the inclusion of biologically functional entities 
such as cell-adhesive peptides or tethered growth factors [133], but differ in other respects. 
The chain cross-linking mechanism is particularly attractive for AM techniques because of 
the fast reaction and spatially directed initiation by light such as in stereolithography. 
However, end-linking polymerization reactions are characterized by a particularly large 
control over the network architecture. For example, it has enabled the preparation of gels 
with the peptide link GCRD-GPQGIWGQ-DRCG, which is cleavable at the “” site by cell-
secreted matrix metalloproteinases (MMPs) [96]. These MMP-cleavable gels (also 
supplemented with covalently bound cell-adhesive peptides) showed ingression of 
migrating and proliferating fibroblasts seeded on the surface of the gels, which was not 
observed in the control gel that was cross-linked with an MMP-insensitive peptide linker. 
Later studies have also shown the possible application of such gels for cell encapsulation 
[134]. In this way, cells can proliferate, migrate and form new tissue while parts of the gel 
that are (still) free of cells remain untouched, retaining the overall shape and mechanical 
stability of the gel. This strategy of cell-mediated degradation mitigates the challenge of 
tuning hydrolytic degradation with tissue formation, which is a very site- and condition-
specific  process and therefore difficult to predict. 
 
So far, fabrication of cell-laden PEG structures by AM techniques have mostly employed off-
the-shelf PEG-diacrylates in conjunction with RGD-PEG-acrylate, resulting in gels that 
support cell viability but are non-degradable and therefore of limited use in tissue 
engineering. However, it can be easily envisioned that the aforementioned strategies of 
introducing hydrolysable links, tethered grow factors and enzyme-sensitive cleavage sites 
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will also be used with alternative hydrogel platforms such as thermo-sensitive PEG-PPO-
PEG, allowing the application in AM technologies. 
 
Fig. 11. Schematic representation of the initial monomer molecules and cross-linked 
polymer networks formed through (A) chain-cross-linking polymerization mechanism (B) 
end-linking mechanism and (C) mixed-mode mechanism.  
 
4.3.2. Mechanical properties 
A specific disadvantage of hydrogels is that their mechanical strength is mostly far below 
that of load-bearing tissues, such as cartilage. This fact has not been appropriately 
addressed by researchers working with hydrogels in tissue engineering, particularly for cell 
encapsulation. The lack of strong and tough hydrogels is one of the main limiting factors in 
advancing tissue manufacture to larger scales and better quality of TECs. 
 
Hydrogels are intrinsically weak due to the high content of water, which dilutes the network 
of elastically active chains and reduces physical entanglement. Obvious ways to increase a 
gel’s modulus and strength are increasing the polymer concentration and cross-link density; 
however this is often detrimental for cell viability and function [95], and for the production 
and distribution of matrix components [100]. Recent developments in areas outside of 
biomedical engineering have resulted in hydrogels with novel chemical structures that have 
considerably improved mechanical properties due to the introduction of an energy-
dissipating mechanism, thereby increasing toughness and (tear) strength while still 
containing high water volume fractions [135]. These include slide-ring gels, double-network 
gels and nanocomposite gels. Particularly the latter two classes of gels show very high 
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toughness and compressive strengths, while retaining flexibility and high water-content. 
Gong et al. have prepared double-network gels with remarkably high compressive strengths 
of up to 17 MPa at a similarly remarkable strain at failure of 92 %, while the water content 
was as high as 90 % [136].  
 
Relatively densely cross-linked networks were swollen in solutions of a second monomer 
and cross-linker, followed by formation of the reinforcing second, interpenetrating network, 
which has a relatively low cross-link density but higher concentration than the first network. 
As a result of the high degree of swelling in the monomer solution, the first gel network is 
highly extended in the final product while the second network is relaxed, which results in 
much stronger reinforcing effects than in conventional interpenetrating networks. These 
networks are currently under investigation for use as artificial articular cartilage with 
promising initial results [137]. In the translation of the double-network strategy to cell 
encapsulation and tissue manufacturing, the major problem is that low-molecular-weight 
monomers are generally cytotoxic [138]. However, reinforcement of gels with encapsulated 
cells using this strategy is more feasible using double bond-functionalized macro-monomers 
of intermediate molecular weights, or with other non-cytotoxic network-forming 
components such as physically cross-linked gels or self-assembling peptides [139]. 
 
Nanocomposite gels are another class of hydrogels exhibiting mechanical properties 
superior to conventional hydrogels. These are water-swollen networks of hydrophilic 
polymers, physically cross-linked through adsorption of the polymer chain ends on 
nanometer-sized inorganic (clay) platelets. The nature of the cross-links being considerably 
large planar sheets with high junction functionality somehow yields unusual mechanical 
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properties, including very good toughness, high elongation at break and ultimate stress 
(both in tension and compression) up to several MPa [140]. Generally, they are synthesized 
through the in situ free-radical polymerization of N-isopropylacrylamide (NIPAAm) in an 
aqueous mixture with clay particles. Recent developments included the replacement of the 
redox initiating system with photo-initiation, greatly increasing the usefulness for patterning 
and processing with AM techniques to form designed structures. Poly(NIPAAm) 
nanocomposite gels can be used for cell culture on the gel surface and subsequent 
detachment of cell sheets without the use of proteases (see also section 3.3.2) [141], but 
the in situ polymerization of the toxic monomer NIPAAm does not allow for cell 
encapsulation. However, most recently nanocomposite gels have successfully been 
prepared from four-armed PEG macromonomers of 20 kg/mol molecular weight [142], 
which is a big step towards the applicability of this gel reinforcing strategy in additive tissue 
manufacture.  
 
Besides double-networks and nanocomposite gels, other approaches have been followed 
attempting to synthesize strong hydrogels for a variety of applications, some of which may 
be translatable to tissue manufacture. The interested reader is referred to the review by 
Calvert [143] for a more comprehensive overview. 
 
4.3.3. Hybrid structures 
Since water is a crucial component of living systems and a major component in most tissues, 
the processing of cells into designed hydrogel structures seems a logical approach. 
However, most organisms are not only composed of hydrated cell-rich tissues, but also of 
more ‘dry’ and protein-rich ECM such as bone and tendon. Therefore, co-manufacturing of 
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solid biodegradable material (polymers, ceramics) with cell-laden hydrogels could combine 
favorable mechanical properties with cells positioned at defined locations at high densities. 
Recently, this approach was successfully applied for the generation of organized viable 
constructs by alternate deposition of thermoplastic fibers and cell-laden hydrogels (Fig. 12) 
[144]. The resulting mechanical properties of the constructs were significantly improved and 
could be tailored within the same range as those of native tissues. Moreover, the approach 
allows the use of multiple hydrogels, and can thus build constructs containing multiple cell 
types or bioactive factors. Furthermore, since the hydrogel is supported by the 
thermoplastic material, a broader range of hydrogel types, concentrations and cross-link 
densities can be used compared to the deposition of hydrogels alone, thereby improving the 
conditions for encapsulated cells to proliferate and deposit new matrix. 
 
Fig. 12. Co-manufacturing of solid biodegradable materials with cell-laden hydrogels. A. 
Schematic overview of a hybrid bioprinting process encompassing alternating steps of 
printing polymer and cell-laden hydrogel, yielding hybrid constructs. B. Layering of the 
dye-containing alginate results in specific confinement of the printed hydrogels C. High 
cell viability as demonstrated by fluorescent Live/Dead assay. Scale bars represent 2 mm. 
Reproduced with permission from (2011) IOP [144] (doi:10.1088/1758-5082/3/2/021001). 
 
A different possible approach is by taking advantage of the membrane-forming self-
assembly process that occurs when solutions of hyaluronic acid and particular types of 
peptide amphiphiles are brought into contact [145]. Computer-controlled deposition of one 
of the components with suspended cells into the second component would lead to a cell 
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suspension (potentially gelled by photo-cross-linking) immobilized in membrane-surrounded 
strands. 
 
4.4. Vascularization 
In spite of considerable attempts in bioengineering functional tissues and organs, most 
applications of tissue engineering have been restricted to avascular or thin tissues, as 
without blood vessels, nutrients and oxygen cannot diffuse into and out of TECs to retain 
cellular viability. As cells existing more than a few hundred microns away from the nearest 
capillaries would undergo hypoxia, apoptosis and ultimately cell death, vascularization is 
one of the major challenges tissue engineers are faced with in the 21st century. Particularly 
with the demand from a clinical point of view to fabricate large TECs in which overcoming 
transport limitations becomes increasingly difficult. From a tissue transplant point of view, it 
is well know that grafts can spontaneously vascularize after implantation, due to an 
inflammatory wound-healing response and the hypoxia-induced endogenous release of 
angiogenic growth factors [151]. The process of angiogenesis follows from a complex 
cascade of events including ECs activation, migration, and proliferation, their arrangement 
into immature vessels, addition of mural cells (pericytes and SMCs), and matrix deposition 
as the vessels mature [146]. The molecular mechanisms regulating each of these stages are 
being described, and it is obvious that diﬀerent growth factors act at distinct steps of 
neovascularization. Nevertheless, this induced vessel ingrowth is often too slow to provide 
sufficient nutrients to the cells in the center of the transplanted tissue. Conclusively, the 
limiting step is therapeutic angiogenesis, and both microvascularization and 
macrovascularization are required to provide nutrients and oxygen in 3D.  
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Vascularization with or without biochemical stimulation (e.g., growth factor delivery),  either 
through ingrowth from surrounding tissues or through de novo blood vessel formation from 
co-deposited cells is currently investigated by a number of research groups [147-150]. 
Mimicking biological patterning may be especially useful to control tissue development 
processes such as neovascularization, where unguided or uncontrolled growth can lead to 
pathological eﬀects including tumor growth, metastasis, and deformed vessels. Techniques 
developed for microarray patterning, microcontact printing, micromolding and laser 
photolithography can be translated to AM of tissues to form gradients of growth factors 
within the scaﬀolds or to co-deposit cells. These are highly architecture-dependent 
processes that can benefit from the specific advantages of AM techniques.  
Several strategies for vascularization at different levels are being developed [151], as 
illustrated in Figure 13.  First of all, the micro-architecture of any scaffold must allow blood 
vessel ingrowth, thus a pore network with large enough interconnections is a prerequisite. 
AM-produced scaffolds generally have better interconnectivity and lower tortuosity than 
scaffolds fabricated by conventional techniques such as porogen leaching. In addition, 
different levels of porosity can be designed to allow cells to fill smaller pores with new 
tissue while leaving large pore channels available for vascularization (Figure 13A). Such 
scaffold designs would also be beneficial in combination with in vivo prevascularization 
strategies; the use of tortuous scaffolds fabricated by thermally-induced phase separation 
or particulate leaching with arteriovenous loops in vivo has lead to the formation of 
vascularized tissue but in pores with small interconnections too distant from the AV loop the 
tissue was prone to necrosis in the longer implantation time points [153] (Figure 13B). 
Furthermore, AM techniques can aid vascularization by site-specific delivery of angiogenic 
factors, possibly released on demand by cell-produced enzymes (Figure 13C). Finally, AM 
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can be employed for the precise co-deposition of gels with relevant cells types (endothelial 
cells, myoblasts, fibroblasts) to guiding migration, proliferation and network formation. This 
will likely improve and accelerate in vitro prevascularization (Figure 13D). 
 
Fig 13. The most direct approach to providing the necessary cues and allowing cells and 
tissues to control the ultimate shape of the engineered tissue and associated vasculature 
is direct fabrication of functioning tissue.  Different strategies for improving 
vascularization of TECs. (a) Scaffold design. Panel (i) shows a scaffold with meso-scale 
porosity (250 m) in which cells can proliferate and deposit matrix, while in panel (ii) the 
same scaffold (enlarged depiction) has added macro-scale channels (visualized in red) of 
600 m. Partly adapted, with permission, from Elsevier (2010) [152]. (b) In vivo 
prevascularization. An artery and a vein were joined via a loop, which was then placed in a 
chamber and implanted, resulting in a highly vascularized construct that was obtained 
eight weeks after implantation. Tortuous foam scaffolds not fabricated by AM show tissue 
necrosis in small and poorly connected pores at a distance from the loop. Reproduced 
with permission, from Elsevier (2006) [153]. (c) Growth factor delivery. Fibrin gel matrices 
were placed on a chicken chorioallantoic membrane. Panel (i) shows the effects of freely 
diffusible VEGF121, whereas in panel (ii) VEGF121 was released enzymatically by MMPs in 
a cell-demanded release, leading to a more regular organization of the vascular structures 
can be observed. Adapted, with permission, from Wolters Kluwer (2004) [154]. (d) In vitro 
prevascularization. Mouse myoblast cells (C2C12) were combined with human umbilical 
vein endothelial cells (HUVECs) and mouse embryonic fibroblasts (MEFs) and seeded on a 
scaffold (panel iii-1), resulting in the formation of a 3D prevascular network (panels i and 
iii-2). After implantation, the network anastomosed to the mouse vasculature (panels ii 
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and iii-4). Partly adapted, with permission, from Nature Publishing Group (2005) [155]. 
Panel d-iii and captions for (c) and (d) adapted, with permission, from Elsevier (2008) 
[151]. 
 
4.5. Scale-up of the AM process 
An additional challenge in the development of current lab-based attempts of tissue 
manufacture towards clinical application is the gradual scale-up of the process. Going from 
the millimeter scale that current work is focused on, to the centimeter scale of tissues or –
eventually– the decimeter scale of organs implies an increase in material volume, numbers 
of cells and possibly construction time by a factor of 103 or 106, respectively.  With such 
scale-up, transport limitations, as well as acquiring adequate cell quantities become 
increasingly difficult. Currently, to obtain sufficient numbers of cells cell populations (either 
differentiated cells harvested from a patient or stem cells) are mostly expanded in 2D 
monolayer using tissue culture flasks. The manual seeding, splitting and harvesting is not 
only labor-intensive and expensive but also lacks high reproducibility, and most importantly 
it is also insufficient for obtaining large enough numbers of cells for manufacture of TECs of 
clinical relevance. Additive tissue manufacture techniques might not develop without the 
concurrent development of automated 3D cell culture systems [23], which can be based on 
suspended microcarriers [156] or fluidized bed bioreactors [157]. This concept however 
appears slow to be embraced, and a roadmap has been established to overcome scientific, 
regulatory and commercial challenges in order to implement a new bioreactor-based 
paradigm [158]. 
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Furthermore, by seeding of pre-fabricated scaffolds with cells, the seeding density and 
efficiency that can be achieved may not be as high as by encapsulation of cells inside 
hydrogels. Native tissues often contain millions of cells per mL of volume, and the direct 
manufacture of tissue precursors with similar cell densities might be a better approach than 
the preparation of constructs with considerably lower densities, requiring extensive in vitro 
culture. This approach has been followed by the preparation of cell-laden hydrogels by 
photo-initiated cross-linking of methacrylated gelatin and hyaluronic acid with densities up 
to 100 million cells/mL [91]. 
 
4.5 Regulatory and commercialization aspects 
Fundamentally, academia and business operate on very different models. Academia has the 
need to publish results ﬁrst, and emphasis is put on the ability to ﬁrst discover a method or 
technique; there is often little, if any, reward for a researcher who perfects the technology 
or veriﬁes and expands the initial results, even if the modiﬁed process is a substantial leap 
over the original research. However, in today’s world time is a precarious factor and hence 
manufacturing R&D must closely follow discovery to ensure that companies can transform 
innovation into products invention and business performance in the tissue engineering 
industry [159]. As a result, the speed at which small enterprises and the biotechnology 
industry at large can translate AM research into high-value-added products and high 
efficiency processes is critical. Realizing this potential requires progress on many fronts of 
science and engineering. Government funds for regenerative medicine research have 
created some of the most sophisticated institutes and laboratories around the world.  Yet, 
research to date has been largely focused on the discoveries with a notable absence of 
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capabilities and funds focused on scale-up of manufacturing or clinical trials, which would 
allow moving the research from bench to bedside [15, 160, 161]. 
Scale-up of manufacturing processes from small lot sizes to mass production poses the first 
key challenge for the fabrication of TECs. Biomaterial scientists in close collaboration with 
engineers need to upscale current lab-based technologies to economies of scale that allow 
reduced manufacturing costs and accelerated entry of TECs into commercial applications. 
Integrating bottom-up and top-down processes into new manufacturing paradigms is the 
second key challenge. Today’s first and second generation scaffolds are frequently 
manufactured with traditional biomaterials and/or manufacturing techniques, which can be 
prohibitively expensive and/or have limited throughput to reach economics of scale [8]. 
As with all tissue engineering and regenerative medicine products (particularly cell-based 
ones), TECs fabricated by AM will have to go through a long and costly trajectory of toxicity 
testing, pre-clinical testing and clinical testing. Analogous to drug master files, material 
master files will have to be obtained for each material. For some materials that have been 
used with AM such as PCL and PLGA, these material master files have been obtained on 
behalf of companies manufacturing those polymers. New devices based on these (non-
modified) materials can get clearance by the Food and Drug Administration (FDA) relatively 
fast and easily through the so-called 510(k) process [161]. 
Growing barriers between clinical and basic research, along with the ever-increasing 
complexities involved in conducting clinical research, are making it more difficult to 
translate scaffold-based tissue engineering concepts to the bedside [162, 163]. The 
challenge is therefore to manage the broad spectrum of stakeholder expectations 
compounded by the sea of ambiguity that swirls around the evolving regenerative medicine 
industry including its yet to be established supporting business models. Quite correctly 
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patients want therapies today, investors need returns quickly and regulators require safety 
and efficacy studies of adequate length to reassure themselves of the worthiness of the 
medical product before it can be approved for routine clinical use. A great nonmedical 
technology based idea, such as the iPAD, can be invented today and commercialised within 
weeks to months. However, as the medical sector is all too aware, the same is not true for 
medical devices, and certainly not for regenerative medicine-based therapies. These 
challenges are limiting commercial interest in the field and hampering the clinical research 
enterprise at a time when it should be expanding to ‘translate’ fundamental research results 
into practical applications [164]. The translational pathways for clinical testing and 
therapeutic use and the complexity of TECs, often containing a combination of scaffolds, 
cells, and/or growth factors, creates challenges for product characterisation, regulatory 
approval and manufacturing conforming with GMP. Hence, it is necessary to develop a road 
map with low and permeable barriers and a great deal of interaction between academic 
research and industry practice that then eventually provides resources and endorsements to 
help product developers to improve the safety and effectiveness of engineered tissues 
ready for testing in clinical trials.  
 
Successful commercialization ultimately requires regulatory and reimbursement approval, 
and in regard to the former, although the FDA is making progress in the regulation of 
scaffold/cell-based therapies, a thoroughly revised system is needed for the regenerative 
medicine products of the 21st Century. Regulatory agencies thus must develop and approve 
in due time the necessary and appropriate processes for regulating the delivery of safe and 
effective clinical therapies based on advances in regenerative medicine [165]. 
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4.5. Scale-up of the AM process 
An additional challenge in the development of current lab-based attempts of tissue 
manufacture towards clinical application is the gradual scale-up of the process. Going from 
the millimeter scale that current work is focused on, to the centimeter scale of tissues or –
eventually– the decimeter scale of organs implies an increase in material volume, numbers 
of cells and possibly construction time by a factor of 103 or 106, respectively.  With such 
scale-up, transport limitations, as well as acquiring adequate cell quantities become 
increasingly difficult. Currently, to obtain sufficient numbers of cells cell populations (either 
differentiated cells harvested from a patient or stem cells) are mostly expanded in 2D 
monolayer using tissue culture flasks. The manual seeding, splitting and harvesting is not 
only labor-intensive and expensive but also lacks high reproducibility, and most importantly 
it is also insufficient for obtaining large enough numbers of cells for manufacture of TECs of 
clinical relevance. Additive tissue manufacture techniques might not develop without the 
concurrent development of automated 3D cell culture systems [23], which can be based on 
suspended microcarriers [156] or fluidized bed bioreactors [157]. This concept however 
appears slow to be embraced, and a roadmap has been established to overcome scientific, 
regulatory and commercial challenges in order to implement a new bioreactor-based 
paradigm [158]. 
 
Furthermore, by seeding of pre-fabricated scaffolds with cells, the seeding density and 
efficiency that can be achieved may not be as high as by encapsulation of cells inside 
hydrogels. Native tissues often contain millions of cells per mL of volume, and the direct 
manufacture of tissue precursors with similar cell densities might be a better approach than 
the preparation of constructs with considerably lower densities, requiring extensive in vitro 
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culture. This approach has been followed by the preparation of cell-laden hydrogels by 
photo-initiated cross-linking of methacrylated gelatin and hyaluronic acid with densities up 
to 100 million cells/mL [91]. 
 
4.5 Regulatory and commercialization aspects 
Fundamentally, academia and business operate on very different models. Academia has the 
need to publish results ﬁrst, and emphasis is put on the ability to ﬁrst discover a method or 
technique; there is often little, if any, reward for a researcher who perfects the technology 
or veriﬁes and expands the initial results, even if the modiﬁed process is a substantial leap 
over the original research. However, in today’s world time is a precarious factor and hence 
manufacturing R&D must closely follow discovery to ensure that companies can transform 
innovation into products [159]. As a result, the speed at which small enterprises and the 
biotechnology industry at large can translate AM research into high-value-added products 
and high efficiency processes is critical. Realising this potential requires progress on many 
fronts of science and engineering. Government funds for regenerative medicine research 
have created some of the most sophisticated institutes and laboratories around the world.  
Yet, research to date has been largely focused on the discoveries with a notable absence of 
capabilities and funds focused on scale-up of manufacturing or clinical trials, which would 
allow moving the research from bench to bedside [15, 160, 161]. 
Scale-up of manufacturing processes from small lot sizes to mass production poses the first 
key challenge for the fabrication of TECs. Biomaterial scientists in close collaboration with 
engineers need to upscale current lab-based technologies to economics of scale that allow 
reduced manufacturing costs and accelerated entry of TECs into commercial applications. 
Integrating bottom-up and top-down processes into new manufacturing paradigms is the 
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second key challenge. Today’s first and second generation scaffolds are frequently 
manufactured with traditional biomaterials and/or manufacturing techniques, which can be 
prohibitively expensive and/or have limited throughput to reach economics of scale [8]. 
As with all tissue engineering and regenerative medicine products (particularly cell-based 
ones), TECs fabricated by AM will have to go through a long and costly trajectory of toxicity 
testing, pre-clinical testing and clinical testing. Analogous to drug master files, material 
master files will have to be obtained for each material. For some materials that have been 
used with AM such as PCL and PLGA, these material master files have been obtained on 
behalf of companies manufacturing those polymers. New devices based on these (non-
modified) materials can get clearance by the Food and Drug Administration (FDA) relatively 
fast and easily through the so-called 510(k) process [161]. 
Growing barriers between clinical and basic research, along with the ever-increasing 
complexities involved in conducting clinical research, are making it more difficult to 
translate scaffold-based tissue engineering concepts to the bedside [162, 163]. The 
challenge is therefore to manage the broad spectrum of stakeholder expectations 
compounded by the sea of ambiguity that swirls around the evolving regenerative medicine 
industry including its yet to be established supporting business models. Quite correctly 
patients want therapies today, investors need returns quickly and regulators require safety 
and efficacy studies of adequate length to reassure themselves of the worthiness of the 
medical product before it can be approved for routine clinical use. A great nonmedical 
technology based idea, such as the iPad can be invented today and commercialised within 
weeks to months. However, as the medical sector is all too aware, the same is not true for 
medical devices, and certainly not for regenerative medicine-based therapies. These 
challenges are limiting commercial interest in the field and hampering the clinical research 
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enterprise at a time when it should be expanding to ‘translate’ fundamental research results 
into practical applications [164]. The translational pathways for clinical testing and 
therapeutic use and the complexity of TECs, often containing a combination of scaffolds, 
cells, and/or growth factors, creates challenges for product characterisation, regulatory 
approval and manufacturing conforming with GMP. Hence, it is of necessity to develop a 
road map with low and permeable barriers and a great deal of interaction between 
academic research and industry practice that then eventually provides resources and 
endorsements to help product developers to improve the safety and effectiveness of 
engineered tissues ready for testing in clinical trials.  
 
Successful commercialisation ultimately requires regulatory and reimbursement approval, 
and in regard to the former, although the FDA is making progress in the regulation of 
scaffold/cell-based therapies, a thoroughly revised system is needed for the regenerative 
medicine products of the twenty-ﬁrst century. Regulatory agencies thus must develop and 
approve in due time the necessary and appropriate processes for regulating the delivery of 
safe and effective clinical therapies based on advances in regenerative medicine [165]. 
 
5. Future directions 
Just as advances in information technology, materials, imaging, nanotechnology and related 
fields — coupled with advances in computing, modeling and simulation — have transformed 
the physical sciences, so are they beginning to transform life science [166]. Most recently 
the term convergence has been introduced to describe this change process also in the 
biomedical field.  In general terms convergence was defined and it has in large stimulated 
our rethinking of how scientific research can be conducted.  A major outcome of this 
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rethinking is that areas such as additive tissue manufacturing not only require collaboration 
among research groups but, more deeply, the integration of disciplinary approaches that 
were originally viewed as separate and distinct. This merging of technologies, processes and 
devices into a unified whole will create new pathways and opportunities for scientific and 
technological advancement in the targeted field.  Based on this background, we will 
describe in this section our thinking process related to aspects expected to play an 
important role in the future development of the AM techniques. 
 
5.1. Modular tissue assembly 
As upscaling and automation are specific advantages of AM techniques and a major driving 
force for developing these techniques for tissue assembly, the associated complexities will 
have to be addressed. One approach to solve issues of accuracy, reproducibility, and error 
scaling is to implement the concept of so called “digital fabrication”. It refers to actual 
printing of physical building blocks termed voxels, as opposed to analogue (continuous) 
material commonly used in most conventional manufacturing techniques [167]. The voxels 
are characterized by their self-aligning and interlocking properties, which enable one to 
fabricate objects that are more precise than the fabricator that created it. This is analogous 
to a child with 1 mm hand placement precision assembling LEGO structures with 5 m 
precision. Furthermore, while with analogue techniques errors in accuracy accumulate 
when structures are scaled up, in digital fabrication errors tend to average out. 
 
Several groups using cell aggregates with or without cells have followed the modular 
approach of using standardized building blocks to build up larger structures. For example, 
cell aggregates or microtissues can be fabricated in pre-designed shapes by seeding and 
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culturing in micro-molded well plates and serve as building blocks to assembly multi-cellular 
tissues at a higher level of organization [168]. Otherwise, micro-engineered cell-laden 
hydrogels can be shaped into larger tubes, sphere shells and other shapes gel blocks by self-
assembly when the gels are being restricted at a surface and forced to form a close packing 
[169]. Such strategies might evolve into AM technologies on their own, or it might become 
possible that cell-laden gel blocks such as these be fed to a voxel printer to actively 
assemble complex tissue constructs. Such an approach could also address the issue of 
vascularization, by assembling microgels pre-seeded with endothelial cells and perfusion of 
the interstitial space with medium in a bioreactor [170]. 
 
5.2. Convergence of techniques 
All AM techniques have their specific shortcomings and advantages, particularly in 
combination with specific biomaterials. So far, mechanical engineers have been working 
with widely available polymers in their attempts to develop new manufacturing techniques, 
and biomaterial scientists have been working with commercially available devices in their 
attempts to develop new biomaterials. We foresee the convergence of skills and techniques 
to take AM to a higher level.  
 
The example of stereolithography combined with stepwise addition of material discussed in 
section 4.2 can be further developed into a combined robotic dispensing and 
stereolithography system, in which a layer with coarse structures is first deposited, followed 
by more accurate local modification by a computer-controlled laser. These modifications 
can involve cross-linking of the hydrogel precursor with the intention to discard non-cured 
material afterwards, but it can also be localized matrix modifications such as the increasing 
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of the cross-link density to obtain anisotropic properties, or functionalization of the gel with 
cell-adhesive peptides [171]. Another method to modify the direct cellular environment that 
has not yet been explored is to initiate modification reactions using the cells as 
intermediate. For example, fluorescent light emitted by fluorescein-tagged cells could set 
off reactions in the direct cell surroundings by using eosin Y as an initiator. Fluorescein can 
be excited by an argon laser at 488 nm (blue) and emits around 520 nm (green), which is the 
wavelength around which eosin has a narrow absorption band. Therefore, it would only be 
excited by the green light emitted from cells rather than by the incident blue laser light and 
could as such initiate local reactions. This photo-initiator has been previously employed 
successfully for cell encapsulation [172]. 
 
Other post-manufacture modifications with different techniques to achieve features at 
higher resolutions could include drilling or laser ablation of channels in gel blocks. Such 
channels could be used for perfusion of medium during culture, or for neo-vascularization 
by seeding an (co-)culture of endothelial cells and fibroblasts on the inside walls of such 
channels. 
 
5.3. Automation of pre- and post-manufacturing phases 
While the successful translation of cell-based therapies from bench to bedside has, at least 
in part, been complicated due to regulatory issues, the automation of the production phases 
could facilitate the progress of tissue engineering towards clinical application.  Therefore,  it 
is also important that the assembly phase is integrated with other stages in production and 
culture of tissue constructs with reduced manual intervention. Besides automation of the 
pre-manufacture cell-culturing phase, also post-manufacture cultivation of tissue constructs 
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requires automation and integration with the fabrication phase. 3D hydrogel-based 
constructs with embedded cells can, for example, be produced in one zone of an isolated 
system by means of a multiple-head bioprinter, while afterwards the 3D construct can be 
transferred by a precision robotic arm to a subsequent zone for culture within a bioreactor 
under controlled dynamic conditions. Environmental (aseptic) conditions, including 
humidity, temperature and CO2 can be controlled and monitored within such systems, and 
the integration of the different production stages into a single device will significantly 
reduce the risks of contamination, increase the productivity and will thus increase the 
reproducibility facilitating the ultimate compliance with regulations [158, 173]. 
 
5.4. Manufacturing of tissue-like constructs for drug discovery and/or testing 
Tissue manufacture has predominantly been discussed from a regenerative medicine 
perspective. However, the manufacture of tissue-like constructs can also be of benefit to 
the fields of drug discovery and testing, and for studying disease processes and 
developmental biology. Such studies are being performed using 2D patterning techniques, 
to quickly test the interaction of many parameters via high-throughput screening [174].  
A 3D environment however could provide a more appropriate model than 2D environments, 
which might make drug screening more selective and disease process studies more relevant. 
Printed microtissues will provide a valuable step in the development process of drugs, by 
yielding extra information before expensive and complex in vivo trials. This concepts lead to 
the automated fabrication of tissue-like living constructs not only for regenerative medicine, 
but also as ex vivo drug screening models [175] or for cancer research [24]. It remains to be 
seen if AM techniques will reach similar accuracy and level of complexity as 2D lithography, 
but there will undoubtedly be cases in which the added value of a 3D environment 
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outweighs the limited spatial resolution. A particular advantage of these areas of application 
is that the required scale of manufactured tissues is much smaller than for regenerative 
medicine, so these AM techniques can be used for such applications before the intended 
scale-up to organ-sized constructs with integrated vascular networks has been realized 
[176]. In addition, such concepts can be translated comparatively fast into real world 
applications as they do not need to undergo the regulatory route of implants. 
 
5.5. In situ additive manufacturing 
Apart from fabrication of pre-designed constructs, AM techniques are currently being 
developed for in situ fabrication [177, 178]. This entails the deposition of material into an a 
priori unknown recipient site, requiring an adaptive system that is capable of performing 
real-time imaging, registration and path planning. Cohen et al. printed alginate into complex 
osteochondral defects in a calf femur model [177]. The alginate cross-linking was initiated 
prior to the printing process by mixing in divalent ions, such that no post-processing steps 
were required. Although still in its infancy and presenting considerable technological 
challenges, in situ AM appears to have great potential for clinical applications that require a 
minimally invasive and/or geometrically patient-specific treatment concept. The adaptive 
nature of the process makes it a particularly attractive, omitting the necessity for imaging, 
pre-designing and implantation of a pre-fabricated construct. In situ AM could potentially be 
extended to many fields of trauma surgery and much is to be expected from these 
developments. 
 
6. Conclusion 
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In summary, additive manufacturing will enable the production of cell-containing constructs 
in a computer-controlled manner, thereby bypassing costly and poorly controlled manual 
cell seeding. Although big steps have been taken since the origins early in the past decade, 
the technology is still in its infancy. It is now critical to address key issues in biomaterials 
development (matching degradation to cellular production and providing adequate 
mechanical properties, while achieving rheological properties required for the 
manufacturing process), construct design (including vascularization of the construct), and 
system integration (inclusion of multiple cells, materials and manufacturing processes in a 
sterile and controlled environment). It is also important to pursue the development and 
commercialization of constructs in a manner that is acceptable to regulatory agencies, such 
as the Food and Drug Administration, where they will more than likely be classed as 
“combination products”, to efficiently translate research outcomes to clinical benefits. With 
the joint effort of researchers combining chemistry, mechanical engineering, information 
technology and cell biology, AM techniques can evolve into a technology platform that 
allows users to create tissue-engineered constructs with economics of scale in the years to 
come. 
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